Chronic Venous Disease, Varicose Veins, Venous Ulcers, and Superficial Interventions

55.1Definition and presentation

Chronic venous disease encompasses a spectrum from uncomplicated visible varicosities to active venous ulceration (CEAP classes C2 to C6). It is highly prevalent; in the Edinburgh Vein Study of adults aged 18 to 64 years, truncal varicose veins were present in 40% of men and 32% of women, while chronic venous insufficiency affected 9% of men and 7% of women, with prevalence rising steeply with age Edinburgh Vein Study 1999.

Clinical severity and outcome tracking rely on the standardized CEAP classification and the Venous Clinical Severity Score (VCSS) VCSS Consensus 2010 · CEAP Update · 2020. Presentation severity, rather than patient age, dictates the necessity of intervention. Presenting features that trigger vascular specialist referral include:

• Symptomatic varicose veins
• Venous skin changes (eczema, hyperpigmentation)
• Superficial vein thrombosis
• Healed or active leg ulceration

These clinical thresholds separate uncomplicated varicosities from advancing disease requiring duplex mapping and potential intervention NICE CG168 2013.

The clinical (C) axis grades the limb, then annotates each grade with E (etiology), A (anatomy), and P (pathophysiology) CEAP Update · 2020.

The 2020 update added the recurrent descriptors C2r and C6r and split C4 to carry C4c corona phlebectatica CEAP Update · 2020.

55.2Diagnosis and mapping

Duplex mapping bridges clinical classification and treatment selection by identifying whether symptoms or ulceration correlate with targetable superficial truncal reflux. The assessment isolates great saphenous, small saphenous, or anterior accessory saphenous vein (AASV) incompetence from isolated tributary disease. Reflux is timed with the patient standing or in reverse Trendelenburg during distal augmentation: outward flow lasting more than 0.5 s defines pathologic reflux in the superficial trunks (GSV, SSV, AASV, tributaries) and the deep femoral vein, while the femoral and popliteal veins require reflux longer than 1.0 s. A perforator is incompetent when outward flow exceeds 0.5 s and its diameter is 3.5 mm or greater ESVS 2022. Modality selection relies on this anatomic map; outcomes specifically for AASV insufficiency treated with endovenous laser ablation (EVLA) demonstrate that non-great-saphenous targets require distinct consideration SVS/AVF/AVLS Part II 2023 · SVS/AVF/AVLS Part I 2022 · AASV EVLA Cohort 2026.

When clinical severity, extreme swelling, or ulcer behavior is disproportionate to the mapped superficial reflux, the diagnostic focus broadens to assess deep venous obstruction or pelvic and splanchnic reflux sources ESVS 2022.

55.3Medical and conservative therapy

Compression therapy is the foundation of venous leg ulcer care and accelerates healing compared to no compression Cochrane Compression vs None 2021 · Cochrane Compression 2012. Measure the ankle-brachial pressure index before any compression. Full high compression near 40 mmHg is safe when ABPI is 0.8 or higher. An ABPI of 0.5 to 0.8 signals mixed arterial and venous disease and calls for reduced, modified compression under specialist supervision, and ABPI below 0.5, or an absolute ankle pressure under 60 mmHg, contraindicates compression ESVS 2022. Multi-layer high-compression systems achieve superior ulcer healing rates compared to single-layer low-compression systems, while four-layer and short-stretch bandages are comparable in efficacy. Dose an active ulcer to an interface pressure of roughly 40 mmHg at the ankle, and prefer a multicomponent system over a single-layer bandage for healing.

For ulcer recurrence prevention, higher-compression hosiery (European or UK class 3) is more effective than lower compression or no compression. However, class 2 compression is better tolerated, making patient adherence the primary determinant of long-term success Cochrane Compression Recurrence 2024.

Adjunctive pharmacotherapy is indicated for selected venous ulcer patients. Pentoxifylline 400 mg three times daily combined with compression improves complete ulcer healing rates compared to compression alone (relative risk 1.70), though gastrointestinal upset is a common limitation Cochrane Pentoxifylline 2012. Sulodexide, an oral glycosaminoglycan, also demonstrates efficacy as an adjunctive therapy for venous leg ulcer healing Cochrane Sulodexide 2016.

55.4Treatment decision and intervention

Superficial intervention is indicated for symptomatic truncal reflux, skin changes, and ulceration. For great saphenous vein incompetence, endovenous thermal ablation (laser and radiofrequency) and foam sclerotherapy achieve technical success and quality-of-life improvements comparable to conventional surgical stripping Cochrane GSV Interventions 2021. Alternative approaches include mechanochemical ablation (MOCA), cyanoacrylate closure, and hemodynamic strategies (CHIVA), chosen based on the mapped reflux pattern and patient anatomy Cochrane CHIVA 2021 · MOCA vs EVLA 2020 · VeClose 5-Year Trial 2020 · Rasmussen RCT 2011.

Age alone is not an exclusion criterion for intervention. Patients older than 70 years achieve clinically meaningful quality-of-life and symptom improvements following endovenous ablation comparable to younger cohorts; frailty and life expectancy govern the decision US Venous Registry 2017.

The stepwise logic for procedural intervention is:

1. Confirm targetable truncal reflux and rule out dominant deep or pelvic disease.
2. Optimize compression therapy and assess adherence.
3. Assess ulcer duration; proceed to early ablation combined with compression for active ulcers of less than 6 months duration.
4. Select endothermal ablation as the default initial intervention for anatomically suitable saphenous truncal disease.
5. Utilize foam sclerotherapy, non-thermal non-tumescent methods, or surgery when thermal ablation is anatomically unsuitable.

55.5Follow-up and complications

Post-procedural surveillance relies on standardized VCSS documentation to track symptom resolution, skin changes, and ulcer healing. Surveillance intervals track symptom and wound response rather than a fixed calendar, with reassessment guided by clinical severity scoring VCSS Consensus 2010. Superficial venous surgery and endovenous correction of reflux decrease long-term ulcer recurrence rates EVRA 3-Year Follow-up 2020 · ESCHAR Trial · 2004. ESCHAR quantified the prevention benefit: adding superficial reflux surgery to compression left 24-week healing unchanged (65% versus 65%) but cut 12-month ulcer recurrence from 28% to 12%.

Post-ablation complication screening specifically evaluates for endothermal heat-induced thrombosis (EHIT). The EHIT consensus terminology dictates complication categorization and subsequent management pathways, distinguishing transient post-procedural phenomena from clinically significant thrombosis SVS/AVF/AVLS Part II 2023 · EHIT Consensus 2021.

The AVF/SVS scheme grades thrombus extension at the saphenous junction and drives treatment EHIT Consensus 2021.

55.6Areas of controversy

• Long-term durability of non-thermal modalities: While thermal ablation, foam, mechanochemical ablation, and cyanoacrylate closure demonstrate definitive early efficacy, comparative recurrence data beyond five years remain sparse, and evidence certainty across modalities ranges from low to moderate Cochrane GSV Interventions 2021 · Cyanoacrylate Cohort 2026.
• Early ablation in chronic or complex ulcers: The EVRA trial robustly supports early superficial ablation for venous ulcers of less than 6 months duration, but the degree of benefit in long-standing, complex, or mixed-etiology ulcers remains less defined EVRA 3-Year Follow-up 2020 · EVRA Trial 2018.